On Saturday, April 18, 2026, President Donald Trump signed an executive order (“Order”) which he proclaimed would “dramatically accelerate access to new medical research and treatments based on psychedelic drugs.” Joe Rogan was there for some reason; Trump joked about trying ibogaine, too. Trump also took the opportunity to complain that his other executive order on controlled substances—marijuana—seems
Over the past few years, I have received countless requests to help people reduce liability when operating a foreign retreat. Most of these retreats involve ketamine, psilocybin, ayahuasca, and/or cannabis. Typical locations include Jamaica, Costa Rica, and Mexico. The laws in these countries, discussed below, can allow operators to conduct retreats with limited exposure if
Facilitating International Psychedelic Retreats
A potential expansion of the religious use of psychedelic substances
Ninth Circuit sides with DEA on doctors petition to seek waiver under Right to Try laws
The end of 2024 marks two years in the books for the Oregon Psilocybin Services (OPS) program. It has been a long road: in my year-end 2023 post, I explained that the program was incubated on a protracted, two-year runway prior to launch. This mean we are four years along, with two years of live
Over the last few weeks, the federal government has taken a number of actions that signal a dark future for psychedelic therapies. Today we'll take a quick look at what's happened, and what may happen in the future. FDA gives thumbs down to MDMA Earlier in August, the FDA opted not to approve Lykos Therapeutics'
Oregon’s rule limiting the non-resident ownership of licensed psilocybin businesses sunsets on December 31, 2024. That’s a little over six months away. Six months is not that long, especially in the context of getting to know an industry or a business, and putting a thoughtful deal together-- one that will generate reasonable returns for an
Despite decades of stigma and legal barriers, recent years have brought a profound shift in attitudes towards psychedelics. Driven by scientific inquiry and a growing recognition of their potential therapeutic benefits, the benefits of psychedelics are being explored. In this blog post, we explore the impact of an unexpected catalyst driving progress in psychedelics research--
Psilocybin's therapeutic renaissance Once relegated to the realm of recreational drug use, psilocybin is now at the forefront of a discussion on the potential therapeutic benefits of psychedelics. Arizona is the latest state to take up the discourse: its proposed Senate Bill 1570 (SB 1570) would establish licensed psychedelic-assisted therapy centers, and advance scientific research
